In this article, we will discuss Epirubicin and Secondary Leukemia. So, let’s get started.
Epirubicin and Secondary Leukemia
The occurrence of secondary acute myelogenous leukemia, with or without a preleukemic phase, has been reported in patients treated with anthracyclines. Secondary leukemia is more common when such drugs are given in combination with DNA-damaging antineoplastic agents,
when patients have been heavily pretreated with cytotoxic drugs, or when doses of the anthracyclines have been escalated. These leukemias can have a short 1- to 3-year latency period.
Epirubicin is mutagenic, clastogenic, and carcinogenic in animals.